Censa Pharmaceuticals completes Phase I study and initiates enrollment into Phase II studies

WELLESLEY, MA – November 1st, 2018, Censa Pharmaceuticals Inc., a biopharmaceutical company focused on the development of CNSA-001 for orphan diseases, announced that it has successfully completed a Phase I study and has initiated enrollment into several Phase II studies.  The Phase I study showed CNSA-001’s favorable safety profile and promising pharmacokinetic & pharmacodynamic characteristics. … Continue reading Censa Pharmaceuticals completes Phase I study and initiates enrollment into Phase II studies